Showing results (641-650 of 727) with videos related to
Sort By:
Pageof 73
Future Oncology (London, England)|October 3, 2024
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancerBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2024
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN StudyBenjamin J Solomon, Geoffrey Liu, Enriqueta Felip, et al.The Lancet. Oncology|December 29, 2015
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trialAlice T Shaw, Leena Gandhi, Shirish Gadgeel, et al.Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.Nature Communications|December 31, 2024
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphomaJulia Paczkowska, Ming Tang, Kyle T Wright, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.ESMO Open|December 7, 2017
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerFiona Blackhall, D Ross Camidge, Alice T Shaw, et al.Cancer Cell|April 20, 2004
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson, Alice T Shaw, Nicholas A Willis, et al.Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.Ebiomedicine|February 13, 2016
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerRyohei Katayama, Takuya Sakashita, Noriko Yanagitani, et al.Pageof 73